Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ABIRISK

Financiado

Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevanc...

Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders... ver más

28/02/2018

NOVARTIS

33M€

Presupuesto del proyecto: 33M€

Líder del proyecto

NOVARTIS PHARMA AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 29 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2018-02-28 No tenemos la información de la convocatoria

0% 100%

29 Participantes

NOVARTIS

Lider

FUNDACIO HOSPITAL UNIVERSITA...

N.D. | Participante

Leiden University Medical Ce...

N.D. | Participante

GETAID

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CTQ2017-87530-R DISEÑO, SINTESIS Y EVALUACION BIOLOGICA DE NUEVAS SONDAS QUI... 71K€ Cerrado

SAF2015-66193-R UTILIZACION DE MEDICINA DE SISTEMAS PARA LA PREDICCION DE LA... 182K€ Cerrado

BIO2014-52683-R DISEÑO Y EVALUACION DE INMUNOGLOBULINAS COMO MOLECULAS TERAP... 278K€ Cerrado

Target to B-cure Targeting auto reactive B cells by vaccination to cure human... 3M€ Cerrado

SAF2013-45232-R VACUNAS FRENTE A ENFERMEDADES HUMANAS PREVALENTES Y OPTIMIZA... 593K€ Cerrado

BIO2010-17039 AGENTES ANTIMALARICOS Y RESPUESTA INMUNE 242K€ Cerrado

Duración del proyecto: 71 meses Fecha Inicio: 2012-03-01
Fecha Fin: 2018-02-28

Líder del proyecto

NOVARTIS PHARMA AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 33M€

Descripción del proyecto The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recruited per year. This should lead to the constitution of the largest possible cohort in Europe for the study of immunogenicity, a condition critical for the success of the program. ABIRISK will also benefit from the unique expertise of immunologist partners in the development of innovative strategies for predicting the immunogenicity of biopharmaceuticals and for defining its mechanisms. The large number of patients enrolled in the ABIRISK cohorts should make it possible to study the genetic basis of immunogenicity in a new way. We will standardize all clinical and biological information before its integration into a large database for evaluation of the clinical relevance of immunization against biopharmaceuticals and stratification of the risk to patients as a function of factors linked to treatment or to the individual. Computational biology and biostatistical modeling will be used to develop models for predicting immunogenicity that will be validated with the ABIRISK database.The complementarity between the clinical partners from different disciplines, immunologists, methodologists and biostatisticians will create a unique task force for studies of biopharmaceutical immunogenicity. The direct outcomes of the proposed work will be greater understanding of the mechanisms involved in the emergence of anti-drug antibodies, the development of new methods for predicting immunogenicity and a comprehensive view of the respective value of predictive tools, and guidelines for the development of new biopharmaceuticals and patient care.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores